A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
High IGKC Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade
[post]
2022
unpublished
Resistance to Immune Checkpoint Blockade (ICB) constitutes the current limiting factor for the optimal implementation of this novel therapy that otherwise demonstrates durable responses with acceptable toxicity scores. This limitation is exacerbated by a lack of robust biomarkers. In this study, we have dissected the basal TME composition at the gene expression and cellular levels that predict response to Nivolumab and prognosis. BCR, TCR and HLA profiling were employed for further
doi:10.20944/preprints202207.0072.v1
fatcat:ziuw2ajhg5gyfblolmrcdf45kq